Trials / Completed
CompletedNCT00612859
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
A Multicenter, Randomized, Double-Blind, PBO-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 217 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum. This trial was intended to explore LEV's utility in adults with social anxiety disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levetiracetam |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2004-06-01
- Completion
- 2004-06-01
- First posted
- 2008-02-12
- Last updated
- 2013-11-26
Source: ClinicalTrials.gov record NCT00612859. Inclusion in this directory is not an endorsement.